ArticlePharmaceutics2022
Alpinumisoflavone Disrupts Endoplasmic Reticulum and Mitochondria Leading to Apoptosis in Human Ovarian Cancer.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Unlocking the Potential of Bioactive Compounds in Pancreatic Cancer Therapy: A Promising Frontier.Biomolecules · 2025Review
- Alpinumisoflavone ameliorates experimental acute reflux esophagitis in rats via regulation of inflammatory pathway.Acta cirurgica brasileira · 2025Article
- Protective effects of alpinumisoflavone against streptozotocin-induced gestational diabetes mellitus in female rats: mechanistic insights and therapeutic potential.Acta cirurgica brasileira · 2025Article
- Targeting oxidative stress with natural products: A novel strategy for esophageal cancer therapy.World journal of gastrointestinal oncology · 2024Review
- Targeting endoplasmic reticulum stress signaling in ovarian cancer therapy.Cancer biology & medicine · 2023Review
- Alpinumisoflavone Activates Disruption of Calcium Homeostasis, Mitochondria and Autophagosome to Suppress Development of Endometriosis.Antioxidants (Basel, Switzerland) · 2023Article
- The role of NLRP3 inflammasome in hepatocellular carcinoma.Frontiers in pharmacology · 2023Review
- Alpinumisoflavone Impairs Mitochondrial Respiration via Oxidative Stress and MAPK/PI3K Regulation in Hepatocellular Carcinoma Cells.Antioxidants (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Alpinumisoflavone is a prenylated isoflavonoid derived from the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.